BACKGROUND: Our previous study showed that prostate cancer cells overexpress and secrete secretory phospholipases A2 group IIa (sPLA2-IIa) and plasma sPLA2-IIa was elevated in prostate cancer patients. The current study further explored the underlying mechanism of sPLA2-IIa overexpression and the potential role of sPLA2-IIa as a prostate cancer biomarker. METHODS: Plasma and tissue specimens from prostate cancer patients were analyzed for sPLA2-IIa levels. Regulation of sPLA2-IIa expression by Heregulin-α was determined by Western blot and reporter assay. RESULTS: We found that Heregulin-α enhanced expression of the sPLA2-IIa gene via the HER2/HER3-elicited pathway. The EGFR/HER2 dual inhibitor Lapatinib and the NF-kB inhibitor Bortezomib inhibited sPLA2-IIa expression induced by Heregulin-α. Heregulin-α upregulated expression of the sPLA2-IIa gene at the transcriptional level. We further confirmed that plasma sPLA2-IIa secreted by mouse bearing human prostate cancer xenografts reached detectable plasma concentrations. A receiver operating characteristic (ROC) analysis of patient plasma specimens revealed that high levels of plasma sPLA2-IIa, with the optimum cutoff value of 2.0 ng/ml, were significantly associated with high Gleason score (8-10) relative to intermediate Gleason score (6-7) prostate cancers and advanced relative to indolent cancers. The area under the ROC curve (area under curve, AUC) was 0.73 and 0.74, respectively. CONCLUSION: We found that Heregulin-α, in addition to EGF, contributes to sPLA2-IIa overexpression in prostate cancer cells. Our findings support the notion that high levels of plasma sPLA2-IIa may serve as a poor prognostic biomarker capable of distinguishing aggressive from indolent prostate cancers, which may improve decision-making and optimize patient management.
BACKGROUND: Our previous study showed that prostate cancer cells overexpress and secrete secretory phospholipases A2 group IIa (sPLA2-IIa) and plasma sPLA2-IIa was elevated in prostate cancerpatients. The current study further explored the underlying mechanism of sPLA2-IIa overexpression and the potential role of sPLA2-IIa as a prostate cancer biomarker. METHODS: Plasma and tissue specimens from prostate cancerpatients were analyzed for sPLA2-IIa levels. Regulation of sPLA2-IIa expression by Heregulin-α was determined by Western blot and reporter assay. RESULTS: We found that Heregulin-α enhanced expression of the sPLA2-IIa gene via the HER2/HER3-elicited pathway. The EGFR/HER2 dual inhibitor Lapatinib and the NF-kB inhibitor Bortezomib inhibited sPLA2-IIa expression induced by Heregulin-α. Heregulin-α upregulated expression of the sPLA2-IIa gene at the transcriptional level. We further confirmed that plasma sPLA2-IIa secreted by mouse bearing humanprostate cancer xenografts reached detectable plasma concentrations. A receiver operating characteristic (ROC) analysis of patient plasma specimens revealed that high levels of plasma sPLA2-IIa, with the optimum cutoff value of 2.0 ng/ml, were significantly associated with high Gleason score (8-10) relative to intermediate Gleason score (6-7) prostate cancers and advanced relative to indolent cancers. The area under the ROC curve (area under curve, AUC) was 0.73 and 0.74, respectively. CONCLUSION: We found that Heregulin-α, in addition to EGF, contributes to sPLA2-IIa overexpression in prostate cancer cells. Our findings support the notion that high levels of plasma sPLA2-IIa may serve as a poor prognostic biomarker capable of distinguishing aggressive from indolent prostate cancers, which may improve decision-making and optimize patient management.
Authors: Sharon D Morgenbesser; Rajashree P McLaren; Brenda Richards; Mindy Zhang; Viatcheslav R Akmaev; Scott F Winter; Nora D Mineva; Paula J Kaplan-Lefko; Barbara A Foster; Brian P Cook; Michael R Dufault; Xiahong Cao; Clarence J Wang; Beverly A Teicher; Katherine W Klinger; Norman M Greenberg; Stephen L Madden Journal: Prostate Date: 2007-01-01 Impact factor: 4.104
Authors: S Signoretti; R Montironi; J Manola; A Altimari; C Tam; G Bubley; S Balk; G Thomas; I Kaplan; L Hlatky; P Hahnfeldt; P Kantoff; M Loda Journal: J Natl Cancer Inst Date: 2000-12-06 Impact factor: 13.506
Authors: Andrew W Roddam; Michael J Duffy; Freddie C Hamdy; Anthony Milford Ward; Julietta Patnick; Christopher P Price; Janet Rimmer; Cathie Sturgeon; Peter White; Naomi E Allen Journal: Eur Urol Date: 2005-09 Impact factor: 20.096
Authors: Manish I Patel; Jaskirat Singh; Marzieh Niknami; Caroline Kurek; Mu Yao; Sasa Lu; Fiona Maclean; Nicholas J C King; Michael H Gelb; Kieran F Scott; Pamela J Russell; John Boulas; Qihan Dong Journal: Clin Cancer Res Date: 2008-12-15 Impact factor: 12.531
Authors: Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami Journal: JAMA Date: 2004-06-09 Impact factor: 56.272
Authors: G J Wolbink; C Schalkwijk; J W Baars; J Wagstaff; H van den Bosch; C E Hack Journal: Cancer Immunol Immunother Date: 1995-11 Impact factor: 6.968
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: Mario Menschikowski; Albert Hagelgans; Susanne Fuessel; Olga A Mareninova; Liana Asatryan; Manfred P Wirth; Gabriele Siegert Journal: Inflamm Res Date: 2013-09-24 Impact factor: 4.575
Authors: Maged Zeineldin; Derek Jensen; Smita R Paranjape; Nikhil K Parelkar; Iman Jokar; George A Vielhauer; Kristi L Neufeld Journal: Genetics Date: 2014-06-09 Impact factor: 4.562
Authors: Anshuli Razdan; Nathan M Main; Vincent Chiu; Nicholas A Shackel; Paul de Souza; Katherine Bryant; Kieran F Scott Journal: Am J Cancer Res Date: 2021-06-15 Impact factor: 6.166
Authors: Alison L Halpern; Patrick D Kohtz; Jessica Y Rove; Lihua Ao; Xianzhong Meng; David A Fullerton; Michael J Weyant Journal: Mol Cell Biochem Date: 2019-01-25 Impact factor: 3.396